Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Capital Leases (2016 - 2017)

Neurocrine Biosciences filings provide 8 years of Capital Leases readings, the most recent being $544000.0 for Q1 2017.

  • On a quarterly basis, Capital Leases fell 32.76% to $544000.0 in Q1 2017 year-over-year; TTM through Mar 2017 was $544000.0, a 32.76% decrease, with the full-year FY2016 number at $617000.0, down 60.32% from a year prior.
  • Capital Leases hit $544000.0 in Q1 2017 for Neurocrine Biosciences, down from $617000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $3.0 million in Q1 2013 to a low of $544000.0 in Q1 2017.
  • Median Capital Leases over the past 5 years was $2.1 million (2015), compared with a mean of $1.8 million.
  • Biggest five-year swings in Capital Leases: surged 32.63% in 2013 and later tumbled 61.22% in 2016.
  • Neurocrine Biosciences' Capital Leases stood at $2.7 million in 2013, then fell by 17.5% to $2.2 million in 2014, then decreased by 29.67% to $1.6 million in 2015, then plummeted by 60.32% to $617000.0 in 2016, then dropped by 11.83% to $544000.0 in 2017.
  • The last three reported values for Capital Leases were $544000.0 (Q1 2017), $617000.0 (Q4 2016), and $649000.0 (Q3 2016) per Business Quant data.